- Home
- FHTX
as 11-21-2024 2:34pm EST
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 513.7M | IPO Year: | 2020 |
| Target Price: | $16.00 | AVG Volume (30 days): | 129.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $10.25 | Next Earning Date: | 11-04-2024 |
| Revenue: | $25,515,000 | Revenue Growth: | -21.66% |
| Revenue Growth (this year): | -8.69% | Revenue Growth (next year): | 8.77% |
Stock Insider Trading Activity of Foghorn Therapeutics Inc. (FHTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bellon Steven F. | FHTX | Chief Scientific Officer | Sep 9 '24 | Sell | $9.50 | 20,000 | $190,000.00 | 101,957 |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Simply Wall St.
14 days ago
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report
Simply Wall St.
15 days ago
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully
Zacks
17 days ago
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
17 days ago
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
PR Newswire
a month ago
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
TipRanks
a month ago
Foghorn Therapeutics Unveils Clinical Pipeline Progress
GlobeNewswire
a month ago
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.